В США одобрили применение вакцины Johnson & Johnson ren.tv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ren.tv Daily Mail and Mail on Sunday newspapers.
Zydus Cadila gets US health regulator s nod to market high blood pressure treatment drug
Zydus Cadila gets US health regulator s nod to market high blood pressure treatment drug
Drug Firm Zydus Cadila Has Received The US Health Regulator s Green Signal To Market Diltiazem Hydrochloride Capsules, Used To Treat High Blood Pressure, Angina (chest Pain) And Certain Heart Rhythm Disorders, In The American Market.
News Nation Bureau | Edited By : Gautam Lalotra | Updated on: 09 Aug 2017, 02:40:29 PM
New Delhi:
Drug firm Zydus Cadila has received the US health regulator s green signal to market Diltiazem Hydrochloride capsules, used to treat high blood pressure, angina (chest pain) and certain heart rhythm disorders, in the American market.
Zydus Cadila gets US health regulator s nod for thyroid drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg, Cadila Healthcare said in a regulatory filing
PTI | January 23, 2021 | Updated 14:58 IST
Representational Image
Drug firm Zydus Cadila has received final approval from the US health regulator to market Liothyronine Sodium tablets that are used to treat underactive thyroid. Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland.
Explore Now
NEW DELHI: Shares of Biocon fell nearly 4 per cent in Monday s trade after the biotechnology major said that the US health regulator has deferred action on the biologics license application (BLA) for a biosimilar to drug Avastin, used to treat various types of cancers.
Following the development, the stock fell 3.89 per cent to hit a low of Rs 463.05 on BSE.
Biocon s arm Biocon Biologics and Mylan, a subsidiary of Viatris Inc, have been informed by the US Food and Drug Administration (USFDA) of a deferred action on the BLA for MYL-1402O, a proposed biosimilar to Avastin (bevacizumab), Biocon said in a regulatory filing.